Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Start your free trial now

Instant access. No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: ZINGO

« Back to Dashboard
Zingo is a drug marketed by Powder Pharms and is included in one NDA. It is available from two suppliers. There are four patents protecting this drug.

This drug has seventy patent family members in thirty-four countries.

The generic ingredient in ZINGO is lidocaine hydrochloride. There are twenty-nine drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the lidocaine hydrochloride profile page.

Summary for Tradename: ZINGO

Patents:4
Applicants:1
NDAs:1
Suppliers / Packagers: see list2

Pharmacology for Tradename: ZINGO

Ingredient-typeAmides
Drug ClassAmide Local Anesthetic
Antiarrhythmic
Physiological EffectLocal Anesthesia

Clinical Trials for: ZINGO

Tumescent Lidocaine Maximum Safe mg/kg Dosage
Status: Enrolling by invitation Condition: Anesthesia

Lidocaine Infusion as a Treatment for Cocaine Relapse and Craving
Status: Recruiting Condition: Cocaine Addiction

Lidocaine: Effect of Lidocaine in Chronic Cough
Status: Completed Condition: Chronic Cough

Lidocaine Infusion for Chronic Pain in Opioid Dependent Patients
Status: Recruiting Condition: Chronic Pain

Intra-arterial Lidocaine for Pain Control Post Uterine Fibroid Embolization
Status: Recruiting Condition: Uterine Leiomyomas

A Dose-response Study of Lidocaine and Etomidate
Status: Completed Condition: Etomidate Overdose of Undetermined Intent

Subcutaneous Lidocaine For Cancer-Related Pain
Status: Recruiting Condition: Cancer-related Pain

Effect of Intravenous Lidocaine and Dexamethasone Combination on Postoperative Sore Throat, Cough and Hoarseness.
Status: Recruiting Condition: Postoperative Sore Throat, Cough, Hoarseness

Effect of Infusion of Lidocaine, Magnesium and Remifentanil Perioperatively in Patients Undergoing Mastectomy
Status: Recruiting Condition: Postoperative Pain

Comparison Between Lidocaine, Dexmedetomidine, and Their Combined Infusion in Subjects Undergoing Coronary Artery Bypass Graft
Status: Completed Condition: Unstable Angina; Coronary Artery Bypass Graft; Dexmedetomidine; Lidocaine; Myocardial Injury; Arrhythmia; Blood Electrolyte Balance

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Powder Pharms
ZINGO
lidocaine hydrochloride
SYSTEM;INTRADERMAL022114-001Aug 16, 2007RXNo8,540,665<disabled><disabled>
Powder Pharms
ZINGO
lidocaine hydrochloride
SYSTEM;INTRADERMAL022114-001Aug 16, 2007RXNo5,899,880<disabled>Y<disabled>
Powder Pharms
ZINGO
lidocaine hydrochloride
SYSTEM;INTRADERMAL022114-001Aug 16, 2007RXNo6,881,200<disabled>Y<disabled>
Powder Pharms
ZINGO
lidocaine hydrochloride
SYSTEM;INTRADERMAL022114-001Aug 16, 2007RXNo6,004,286<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: ZINGO

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,630,796 Method of delivering powder transdermally with needless injector<disabled in preview>
7,942,846Needleless syringe using supersonic gas flow for particle delivery<disabled in preview>
7,618,394Needleless syringe using supersonic gas flow for particle delivery<disabled in preview>
6,168,587 Needleless syringe using supersonic gas flow for particle delivery<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ZINGO

Country Document Number Publication Date
United Kingdom9326069Feb 23, 1994
European Patent Office0734737Oct 02, 1996
European Patent Office0734737Jun 07, 2006
Taiwan404844Sep 11, 2000
Poland311005Jan 22, 1996
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc